Open AccessAdjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice
Author(s) -
Fukasawa Lucila O,
Dias Waldely O,
Schenkman Rocilda P.F,
Raw I,
Tanizaki Martha M
Publication year - 2004
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/j.femsim.2004.03.005
Subject(s) - neisseria meningitidis , adjuvant , avidity , meningococcal vaccine , microbiology and biotechnology , biology , antigen , antibody , immune system , immunization , vaccination , immunology , meningococcal disease , virology , bacteria , genetics
Meningococcal outer membrane vesicle (OMV) vaccines are weak antigens in infants. This study aimed at investigating alternative adjuvants for induction of functional antibodies in newborn mice. Serogroup B/C anti‐meningococcal vaccines, consisting of capsular polysaccharide from serogroup C (PSC) conjugated to OMV from one serogroup B serosubtype prevalent in Brazil, combined with OMV from another prevalent serosubtype, were tested in newborn and adult mice with the following adjuvants: aluminum hydroxide, MPL (monophosphoryl lipid A), Titermax and MF59. Total IgG, IgG avidity index determination and bactericidal assay were performed with sera from immunized mice. Antibodies induced against PSC in newborn mice showed avidity and bactericidal titers, similar to those obtained in adult mice, independently of the adjuvant. Evidence is presented that the inclusion of MF59 enhanced the immune response against OMV in newborn mice.